Total ureteral replacement with a small intestinal graft as a reconstructive stage of combined treatment for recurrent colorectal cancer: case report - Scorecard - MDSpire

Total ureteral replacement with a small intestinal graft as a reconstructive stage of combined treatment for recurrent colorectal cancer: case report

  • By

  • Sergey K. Efetov

  • Maksim V. Volgin

  • Aleksandra Y. Koziy

  • Igor V. Fokin

  • Camilla R. Azilgareeva

  • Nina B. Paramonova

  • Mikhail E. Enikeev

  • Airazat M. Kazaryan

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Complete Ureteral Reconstruction Using a Small Intestinal Graft in the Multimodal Approach for Recurrent Colorectal Cancer: A Case Study

At a Glance

CategoryDetail
Condition
Key MechanismsTotal ureteral replacement with a small intestinal graft as part of surgical management.
Target Population
Care Setting

Key Highlights

  • Patient underwent low anterior rectal resection and D2 lymph node dissection.
  • Surgical intervention included en bloc resection of recurrent mass and left ureter.
  • Ureteral reconstruction performed using a small intestinal graft.
  • Postoperative adjuvant chemotherapy was administered.

Guideline-Based Recommendations

Diagnosis

  • Use imaging techniques such as CT and pyeloureterography for diagnosis.

Management

  • Surgical intervention is recommended for isolated ureteral metastases.

Monitoring & Follow-up

  • Regular follow-up examinations post-chemotherapy.

Risks

  • High risk of postoperative complications due to extensive surgical intervention.

Patient & Prescribing Data

48-year-old female with recurrent colorectal cancer.

Adjuvant chemotherapy administered post-surgery; no disease progression observed.

Clinical Best Practices

    Related Resources & Content

      Original Source(s)

      Total ureteral replacement with a small intestinal graft as a reconstructive stage of combined treatment for recurrent colorectal cancer: case report

      • by Sergey K. Efetov, Maksim V. Volgin, Aleksandra Y. Koziy, Igor V. Fokin, Camilla R. Azilgareeva, Nina B. Paramonova, Mikhail E. Enikeev, Airazat M. Kazaryan

      • June 1, 2026

      Related Content

      Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

      Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

      Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2